LEVETIRACETAM USE, AVAILABILITY AND KNOWLEDGE OF TOXICITY AMONG EPILEPTIC PATIENTS AND THEIR CARE GIVERS: A CROSS-SECTIONAL STUDY IN KING SALMAN ARMED FORCES HOSPITAL TABUK SAUDI ARABIA
Background: Levetiracetam (Keppra®) is a well-known second-generation anti-epileptic drug (AED). The study was aimed to addresses Levetiracetam use, availability and knowledge of toxicity among epileptic patients and their care givers in King Salman Armed Forces Hospital Tabuk Saudi Arabia. Methods: This cross-sectional survey was conducted in King Salman Armed Forces Hospital (KSAFH) in Tabuk city in Saudi Arabia. The study participants were epileptic patients and their care givers, selected from different outpatient departments using a convenient sampling technique. Data was collected using an Arabic self-reported questionnaire consisted of open-ended and closed-ended questions to facilitate study participants. Altogether, 381 persons answered the full questionnaire. The data were entered into SPSS version 26.0 for Windows, cleaned and managed before analysis. Results: Participants age ranged from 18 to 63 years, with a mean 29.6 years and standard deviation 5.8 years. 47.0% (n= 179) were male and 53.0% (n= 202) female. Six out of ten participants lived in the urban area (67.7%). Majority of the participants had knowledge about seizures (96.9%). About 31.0% of the participants and/or patients had seizures (epilepsy) since more than 20 years. Nearly 28.0% participants and/or patients had family history of seizures (epilepsy). Majority of the participants had Levetiracetam at home and aware of the correct usage of it. However, about 11% of the participants felt that Levetiracetam is used to help sleep. Eight out of ten of the participants reported “Sleepiness” as the side effect of Levetiracetam (79.3%). Half of the participants reported “Headache” as the side effect of Levetiracetam. About 94.0% of the participants knew that someone could take enough Levetiracetam to harm themselves. Conclusion: The study population used Levetiracetam, they demonstrated basic awareness of Levetiracetam use including the potential consequences of overdosing. Participants' knowledge regarding the toxicity of Levetiracetam is adequate. Special awareness programs for parents of children with epilepsy may be needed to reduce the knowledge gaps in the management of epilepsy and to ensure compliance and optimal therapeutic outcomes.